Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 125,990

Document Document Title
WO/2017/119455A1
Provided is a prophylactic or therapeutic agent for autism spectrum disorder, said agent comprising compound (I) that has affinity to melatonin receptors. A compound represented by formula (I) [wherein the meaning of each symbol is as de...  
WO/2017/119481A1
Provided are: a composition for preventing neurological diseases; use of a material for preventing neurological diseases; and a method for preventing neurological diseases. It has been discovered that a particular cyclic dipeptide or a s...  
WO/2017/118307A1
The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and medical uses thereof.  
WO/2017/120409A1
Described are deuterium-substituted tetrahydrocarbazole compounds of Formulae (I), (II), or (III), which are inhibitors of sirtuin 1 (SIRT1). Also described are pharmaceutical compositions comprising the deuterium-substituted tetrahydroc...  
WO/2017/118375A1
Disclosed in the present invention is a Dezocine analogue, and particularly disclosed are compounds represented by formula (I), (II) and (III), a pharmaceutically acceptable salt or tautomer thereof.  
WO/2017/120417A1
Disclosed is a method for reducing or preventing fetal opioid dependence in a drug dependent or opioid tolerant pregnant subject. The method involves administering to the pregnant subject a composition comprising an opioid antagonist in ...  
WO/2017/119456A1
The present invention provides a prophylactic or therapeutic agent for delirium, containing a compound (I) having an affinity for a melatonin receptor. A compound represented by the formula [wherein, each symbol is as defined in the desc...  
WO/2017/119463A1
The present invention can provide a nucleic acid medicine which has a higher α-synuclein-expression-inhibiting effect and can exert this effect sustainably for a longer period. Disclosed is an oligonucleotide which contains at least one...  
WO/2017/120532A1
Provided is a phosphate salt of quinuclidin-4-ylmethyl 4-methyl-1H-indole-3- carboxylate, in particular polymorphic Form A, a process for their preparation of said salt, in particular in polymorphic Form A, and a pharmaceutical compositi...  
WO/2017/118857A1
The present invention provides tacrolimus for use in the treatment in a human subject of a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementias (FTDs), wherein the tacrolimus is for administratio...  
WO/2017/117708A1
Provided herein are compounds of the formula I: as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing t...  
WO/2017/119198A1
It has been strongly required to develop a therapeutic drug for treating meniscus degeneration, i.e., a drug that relieves pain accompanying with meniscus degeneration, exhibits a long-lasting effect and is highly efficacious for healing...  
WO/2017/119476A1
Provided are: a composition for preventing neurological diseases; use of a material for preventing neurological diseases; and a method for preventing neurological diseases. It has been discovered that a heat-treated product of an animal/...  
WO/2017/117569A1
Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical composi...  
WO/2017/115367A1
The present invention provides a composition and method for treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject. The composition a peptid...  
WO/2017/117138A1
An apparatus for performing cerebral micro-dialysis to treat neurological disease of a patient's brain includes a catheter for implantation in or near the patient's brain, an implantable pump communicated with the catheter to transport c...  
WO/2017/117514A1
This invention relates to novel 2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1, 2,3-de]quinoxalines, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this inve...  
WO/2017/115205A1
Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.  
WO/2017/114597A1
The present invention relates to pharmaceutical dosage forms comprising the hemi-L-tartrate salt of the compound according to formula (I) in particulate form, wherein the particles have a d50 of more than 20 μm and less than 180 μm.  
WO/2017/114322A1
A traditional Chinese medicine for treating paralysis agitans is prepared from the following raw materials in parts by weight: 8 to 20 parts of herba houttuyniae, 10 to 18 parts of baked ginger, 6 to 15 parts of cymbidiumLianpan, 10 to 1...  
WO/2017/115873A1
The invention provides an agent for preventing or treating Alzheimer's disease (AD) that combines two or more compounds selected from the group consisting of compounds represented by compound numbers 1-130. These compounds are existing d...  
WO/2017/113268A1
The present invention relates to a compound for treating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and an application of the compound. The invention discloses a compound suppressing a toxicity induced by an rG...  
WO/2017/117138A8
An apparatus for performing cerebral micro-dialysis to treat neurological disease of a patient's brain includes a catheter for implantation in or near the patient's brain, an implantable pump communicated with the catheter to transport c...  
WO/2017/117121A1
Disclosed embodiments provide nutritional compositions and methods of enhancing maturation of an infant's brain. The methods include the step of administering to the infant a nutritional composition comprising a protein with a degree of ...  
WO/2017/112988A1
The present invention describes molecules with a hybrid nucleus based on tetrahydroacridine and tianeptine nuclei separated by methyl spacer chains via a coupling reaction, a pharmaceutical composition comprising these molecules, a metho...  
WO/2017/117525A1
The present disclosure provides compositions, methods, systems, and apparatuses for treating disorders or illnesses. The composition may comprise at least one substance based on or derived from cocoa beans or coffee beans provided to be ...  
WO/2017/117586A1
The present invention relates to compositions that can be used, for example, in methods of treating medical conditions and symptoms associated with brain dysfunction, including but not limited to Gulf War illness (GWI), multiple chemical...  
WO/2017/114379A1
Disclosed is a nasal gel composition of glatiramer acetate, wherein same is made from glatiramer acetate, a gel matrix and other pharmaceutically acceptable excipients. The other pharmaceutically acceptable excipients comprise from 0.9%-...  
WO/2017/113775A1
The present invention provides an application of a triglyceride compound for use in preparing a medicine for treating neurodegenerative diseases.  
WO/2017/114321A1
A traditional Chinese medicine for treating viral encephalitis is prepared from the following raw materials in parts by weight: 4 to 10 parts of coastal glehnia root, 3 to 8 parts of paniculate swallowwort root, 2 to 7 parts of chastetre...  
WO/2017/115815A1
The present invention relates to a therapeutic agent, a medicine and a treatment method for treatment-resistant depression, persistent depression and/or recurrent depression, in each of which a compound represented by formula (1') or a p...  
WO/2017/117158A1
The present disclosure is directed to methods, compositions, and kits for treating amyotrophic lateral sclerosis.  
WO/2017/113289A1
Disclosed are a ginsenoside Rg1 vitreous cavity injection delivery system and a use thereof in preparing a drug for treating glaucomatous optic nerve damage. The delivery system comprises a ginsenoside Rg1 solution and an ultrasonic cont...  
WO/2017/115789A1
Provided are compositions for recovering and/or ameliorating deterioration of physiological functions due to aging. A cell overexpressing GDF6 protein or an miR-17 family member. A composition for treating aging-related symptoms, said co...  
WO/2017/114225A1
The present invention relates to a fused tricyclic γ-amino acid derivative and a pharmaceutical application thereof. Specifically, the present invention relates to a fused tricyclic γ-amino acid derivative depicted by general formula (...  
WO/2017/114260A1
Provided in the present invention are an indoleamine 2,3-dioxygenase 2 inhibitor and applications thereof. Specifically, provided is a compound as represented by formula I of the present invention or a pharmaceutically acceptable salt th...  
WO/2017/113964A1
Provided is a novel stilbene derivative, being a compound having the general formula (I) or general formula (II), or an acceptable salt formed from the compound having the general formula (I) or general formula (II) with an inorganic aci...  
WO/2017/115705A1
[Problem] To provide a medicinal composition that is capable of improving the prognosis after the restart of the patient's own heartbeat even after the passage of a considerably long period of time after the restart of the patient's own ...  
WO/2017/117529A1
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using ...  
WO/2017/107791A1
The present invention relates to a crystal form of a substituted aminopyran compound, and a pharmaceutical composition, a preparation method and a use thereof in the preparation of a drug for treating type II diabetes. In particular, the...  
WO/2017/112917A1
Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A(A2A) receptor antagonist or a combination of an adenosine-A2A(A2A)receptor antagonist and a ...  
WO/2017/111166A1
According to the present invention, a drug for treating an intracellular TDP-43 content-related disease is developed and provided . In the binding of TDP-43 to a specific mt-tRNA, the binding sites of the respective substances are identi...  
WO/2017/111005A1
A tablet which comprises (1) 1-(3-(2-(1-benzothiophen-5- yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and (2) ethyl cellulose, said tablet having excellent elution properties and good moldability, remaining stable during prolonged st...  
WO/2017/112719A1
The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds descr...  
WO/2017/109300A1
The invention relates to a combination product comprising, as active substances, at least melatonin, passion flower, chamomile and lemon balm or a bioequivalent compound thereof for helping individuals relax and/or fall asleep. The inven...  
WO/2017/107907A1
The present invention relates to a condensed ring γ-amino acid derivative and a medical use thereof, and in particular relates to the condensed ring γ-amino acid derivative as shown in formula (I), or a stereisomer, a solvate, a metabo...  
WO/2017/110705A1
The present invention addresses the problem of developing a drug capable of regrowing synapses, which have been damaged and lost due to a neurodegenerative disease, to thereby provide a medicinal composition for preventing or treating a ...  
WO/2017/107242A1
The present invention relates to a pharmaceutical composition and a preparation method and an application thereof. The pharmaceutical composition consists of cycloserine and an adjuvant, wherein the D90 particle diameter of the pharmaceu...  
WO/2017/111668A1
The invention relates to the field of medicine. A preparation for treating exostoses, headaches and cardiac pain comprises turpentine and formaldehyde and additionally contains ethanol 96% in the following ingredient ratio (in ml per 100...  
WO/2017/109095A1
The invention relates to (hetero) cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.  

Matches 301 - 350 out of 125,990